You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
|
|---|---|
| Published in |
npj Breast Cancer, January 2018
|
| DOI | 10.1038/s41523-017-0053-3 |
| Pubmed ID | |
| Authors |
Sri Lakshmi Hyndavi Yeruva, Fengmin Zhao, Kathy D. Miller, Amye J. Tevaarwerk, Lynne I. Wagner, Robert J. Gray, Joseph A. Sparano, Roisin M. Connolly |
| Abstract |
Endocrine therapies are effective in the treatment of hormone receptor (HR)-positive breast cancer, however, de novo or acquired treatment resistance is a significant clinical problem. A potential mechanism of resistance involves changes in gene expression secondary to epigenetic modifications, which might be reversed with the use of histone deacetylase (HDAC) inhibitors such as entinostat. The ENCORE 301 phase II randomized, placebo-controlled study demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS), with the addition of entinostat to exemestane in patients with HR-positive advanced breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI). These results prompted the development of E2112, a phase III registration trial which is investigating entinostat/placebo in combination with exemestane in patients with locally advanced or metastatic breast cancer who have experienced disease progression after a non-steroidal AI. E2112 aims to validate the preclinical and clinical findings supporting the role of HDAC inhibitors in overcoming resistance to endocrine therapy in breast cancer, and ultimately improve outcomes for patients with advanced breast cancer. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 10% |
| United States | 1 | 10% |
| Unknown | 8 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 68 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 17% |
| Researcher | 9 | 13% |
| Other | 6 | 9% |
| Student > Bachelor | 6 | 9% |
| Student > Master | 5 | 7% |
| Other | 10 | 14% |
| Unknown | 21 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 30% |
| Biochemistry, Genetics and Molecular Biology | 6 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Agricultural and Biological Sciences | 4 | 6% |
| Psychology | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 25 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2019.
All research outputs
#2,225,926
of 23,015,156 outputs
Outputs from npj Breast Cancer
#130
of 505 outputs
Outputs of similar age
#54,194
of 443,312 outputs
Outputs of similar age from npj Breast Cancer
#4
of 7 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 505 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,312 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.